Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective

Shahneen Sandhu; Timothy A. Yap; Johann S. de Bono

doi:10.1016/j.ejca.2009.10.021

Related publications

Article2022

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

Andrisha–Jade Inderjeeth, Monique Topp, Elaine Sanij, Elena Castro, Shahneen Sandhu

Article2011

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment

Shahneen Sandhu, Timothy A. Yap, Johann S. de Bono

Letter2013

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Shahneen Sandhu, Aurelius Omlin, Lucy Hylands, Susana Miranda, Louise J. Barber, Ruth Riisnaes, Alison Reid, Gerhardt Attard, L. Chen, Iwanka Kozarewa, Heidi Gevensleben, James Campbell, Kerry Fenwick, Ioannis Assiotis, David Olmos, Timothy A. Yap, Peter C.C. Fong, Nina Tunariu, Dow‐Mu Koh, L. Rhoda Molife, S.B. Kaye, Christopher J. Lord, Alan Ashworth,

Article2011

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

Timothy A. Yap, Shahneen Sandhu, Craig P. Carden, Johann S. de Bono

Article2020

Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors

Barbara Pasculli, Raffaela Barbano, Andrea Fontana, Tommaso Biagini, Maria Pia Di Viesti, Michelina Rendina, Vanna Maria Valori, Maria Morritti, Sara Bravaccini, Sara Ravaioli, Evaristo Maiello, Paolo Graziano, Roberto Murgo, Massimiliano Copetti, Tommaso Mazza, Vito Michele Fazio, Manel Esteller, Paola Parrella